Gentis is a biotechnology startup that is focused on addressing early-stage spinal degeneration through the development of minimally invasive, biomaterials-based products. The company's flagship product, DiscCell, is an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material designed to supplement or replace the compromised nucleus pulposus within the spinal disc. Founded in 2000 and based in Wayne, Pennsylvania, Gentis has garnered attention for its innovative approach to spinal health.
In July 2010, Gentis received a significant $548.26K Venture Round investment from Matignon Technologies, demonstrating the confidence that investors have in the company's vision and products. This funding is crucial for Gentis to further develop and bring its solutions to market, potentially revolutionizing treatment for early spinal degeneration.
